Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

The purpose of this study is to identify changes in Carbonic Anhydrase IX (CAIX) expression induced by hypoxia-inducible factor 2 alpha (HIF-2α) inhibition by initiating belzutifan single agent therapy and imaging CAIX expression with 89Zr-DFO-girentuximab PET before and 4 weeks after initiating treatment. This will be the first study to evaluate potential changes in CAIX expression altered by belzutifan. Information gained from this study will be leveraged to develop combinations of belzutifan with CAIX targeted agents including radioimmunotherapy in the future.

Trial Details

NCT ID
NCT07179770
Phase
PHASE1
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Belzutifan
  • 89Zr-DFO-girentuximab
  • 89Zr-DFO-girentuximab PET
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologically confirmed advanced clear cell RCC
  • Radiographic disease progression to prior immune checkpoint inhibitor (ICI) therapy for RCC
  • ICI for adjuvant therapy: Patients who experienced radiographic tumor progression during or within 6 months after last dose of adjuvant ICI
  • ICI for locally advanced or metastatic disease: radiographic disease progression during or following ICI treatment in the 1st line setting

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →